Empagliflozin

CAS 864070-44-0 44 current recordsSmall Molecule

Who holds supplier records for Empagliflozin? 44 organisations hold a current record for Empagliflozin: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (30), China (8), Spain (1), Netherlands (1) and 1 other country (1); not recorded for 3.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Empagliflozin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/empagliflozin

Reading the evidence

  • 44 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    30 of the 41 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 21 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Empagliflozin expires 11 Dec 2034. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (44)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Empagliflozin. Country is the organisation's recorded country, not necessarily the manufacturing site.

India30China8Spain1Netherlands1Poland1Country not recorded for 3
Need Empagliflozin sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (4 listed products contain Empagliflozin). The latest listed patent expires 11 Dec 2034. The latest listed exclusivity runs to 20 Dec 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes. It helps lower blood sugar levels by preventing glucose reabsorption in the kidneys, promoting its excretion.

Chemical identity

IUPAC name
(2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Canonical SMILES
C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
InChIKey
OBWASQILIWPZMG-QZMOQZSNSA-N
Synonyms
bi-10773, bi10773, glyxambi component empagliflozin, jardiance, trijardy xr component empagliflozin

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of action
Sodium-Glucose Transporter 2 Inhibitors

Therapeutic areas

DiabetesCardiovascularEndocrinology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Empagliflozin?

44 organisations hold an active US FDA Type II Drug Master File or a CEP for Empagliflozin: Dr. Reddy's Laboratories Ltd. (India), HONOUR LAB LTD (India), EMNAR PHARMA PRIVATE LTD (India), Mankind Pharma Limited (India), MSN LIFE SCIENCES PRIVATE LIMITED (India), Zhejiang Huahai Pharmaceutical Co., Ltd. (China), Zydus Lifesciences Limited (India) and AARTI PHARMALABS LIMITED (India), and 36 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Empagliflozin Drug Master Files are active?

Dr. Reddy's Laboratories Ltd. (DMF 32349, 32477), HONOUR LAB LTD (DMF 40332, 32534), EMNAR PHARMA PRIVATE LTD (DMF 36742, 41237), Mankind Pharma Limited (DMF 41404, 40847), MSN LIFE SCIENCES PRIVATE LIMITED (DMF 32161, 32662), Zhejiang Huahai Pharmaceutical Co., Ltd. (DMF 37867, 32385), Zydus Lifesciences Limited (DMF 43815, 32378) and AARTI PHARMALABS LIMITED (DMF 42587) and 36 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Empagliflozin?

Yes. The latest patent listed for an approved US product containing Empagliflozin expires 11 Dec 2034, across 4 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Empagliflozin supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Empagliflozin?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.